GI Oncology Now brings you the latest research and updates in #livercancer, #coloncancer, #pancreaticcancer, and more in the gastrointestinal oncology sphere.
- Tweets 1,052
- Following 160
- Followers 433
- Likes 50
📺 Dr. Josep Llovet of @MountSinaiNYC discusses the mature findings of the LEAP-012 trial, which showed an improvement in PFS in intermediate-stage #hepatocellular carcinoma with lenvatinib + pembrolizumab and TACE, but did not meet its primary end point: buff.ly/gvvL8hD
1
3
132
🔎 Adjuvant atezolizumab is linked to beneficial estimated 2-year DFS and OS rates, respectively, in patients with stage III MSI-H or dMMR #colorectalcancer who were ineligible for oxaliplatin-based chemotherapy, according to results presented at #ESMO26: buff.ly/nny8s6x
69
💊 A study presented at the 2026 @myESMO Congress has revealed that #encorafenib and #cetuximab retreatment is ineffective in BRAFV600E-mutant metastatic #colorectal cancer without common genomic drivers of EC resistance in ctDNA: buff.ly/p2llAwJ
1
79
🔎 The preliminary results of a phase 1 study presented at #ESMO26 have shown that the investigational KRAS inhibitor QTX3034 can provide encouraging antitumor activity in combination with #cetuximab among patients with KRASG12D-mutated #colorectalcancer: buff.ly/ytepRWW
1
116
🚨 #ESMO26 is finally here! Keep an eye on our conference page to stay up-to-date on the latest updates in the GI oncology field: buff.ly/4n8OG2F
1
69
💊 The use of #daraxonrasib for pancreatic cancer features a toxicity profile that differs from many traditional therapies.
📺 GI oncology pharmacist Elizabeth Dow-Hillgartner shares insight on what to know regarding the treatment's adverse effects: buff.ly/YB1UHyW
87
📺 Part two of our interview with @jgong15 on targeting #pancreatic cancer metabolism through glutamine supplementation focuses on the translational and biomarker findings from the GlutaPanc trial, including insights into the gut microbiome: buff.ly/Yh4gXsV
2
3
100
❗️ Updated results from the phase 3 NRG-GI003 trial have shown that proton therapy does not improve OS in patients with advanced #hepatocellular carcinoma and did not improve the trial’s secondary end points, which included PFS and local progression: buff.ly/6TjBEf5
106
❗️ The FDA has just approved #dostarlimab for the treatment of locally advanced rectal cancer - read to learn about the positive trial results of AZUR-1 that led to its approval: buff.ly/kDMvhgY
1
119
🔎 Results from the phase 2 portion of the ASPEN-06 trial have demonstrated the benefits of #evorpacept with #trastuzumab, #ramucirumab, and #paclitaxel for patients with pretreated advanced HER2+ #gastriccancer: buff.ly/zCv8Dq2
1
1
107
📺 In a new interview with Dr. Jun Gong of Cedars-Sinai, he examines a novel and unconventional approach to targeting #pancreatic cancer metabolism through glutamine supplementation: buff.ly/Dp5lDaG
2
1
713
❗️ Early-onset cancers are rising worldwide, with the greatest increase in incidence seen in GI malignancies.
🔎 Learn how oncologists are researching potential cancer drivers to determine what's on the horizon for GI cancer treatment: buff.ly/FOvDmpC
2
6
509
Rest in peace, Dr. Rachna Shroff.
A distinguished leader, she expanded access to clinical trials and advanced pancreatic cancer care at The University of Arizona Cancer Center. Her innovation and dedication will continue to shape the field of GI oncology. buff.ly/SbQyoOm
1
15
407
👉 Stay up-to-date in the fast-moving field of GI oncology by taking a look back at our top five posts from September, including research into targeting FGFR2b in #cholangiocarcinoma, and new insights on neoadjuvant chemotherapy for #gastric cancer: buff.ly/1S5Geit
1
1
142
📺 Check out our 2-part discussion with Elizabeth Dow-Hillgartner of @UWHealth, where she shares guidance on recognizing and managing key adverse events associated with #daraxonrasib, which was recently approved by the FDA for #pancreatic cancer: buff.ly/J2BfZJX
2
228
🔎 An externally validated causal machine learning framework, presented at the 2026 @ASTRO_org Annual Meeting, has found that proton beam therapy can provide a greater survival advantage in patients with #hepatocellular carcinoma and smaller tumors: buff.ly/rIxLoPn
99
❓ Can #sintilimab provide better pathological complete response in patients with locally advanced esophageal squamous cell carcinoma when added to neoadjuvant chemoradiotherapy? Learn about the results presented at the 2026 @ASTRO_org Annual Meeting: buff.ly/8QDxAc2
90
🔎 Updated results from the NEO-CRAG trial have found that the use of preoperative #chemoradiation can improve disease control in locally advanced #gastriccancer: buff.ly/BHj4zPB
4
124
🔎 Combined SBRT and immunotherapy may be a curative treatment approach for patients with locally advanced unresectable #hepatocellular carcinoma, based on an updated 5-year follow-up analysis of overall survival presented at the 2026 ASTRO Annual Meeting: buff.ly/hb8EWHw
2
5
225
🔎 An update on the phase 3 NEO-CRAG trial presented at the 2026 @ASTRO_org Annual Meeting has reported the impact of pre-treatment staging laparoscopy on tumor control and survival comparisons in patients with #gastriccancer: buff.ly/BHj4zPB
1
1
71